The author reviews the various tools of pain control in rheumatic disorders, with special attention to the pharmacological modalities, focusing on the use of cyclo-oxygenase inhibitors (coxibs). The new pain control drugs have different side-effect profiles, and even though these are more favourable than those of the traditional drugs, not all of them meet the strict safety requirements. The new drugs that are available in Hungary have a lower gastrointestinal side effect risk than the traditional nonsteroidal anti-inflammatory drugs, still with comparable effectiveness. The non-steroidal antiinflammatory drugs - including the selective cyclo-oxygenase inhibitors - increase the risk of cardiovascular disease, though to varying extent. When choosing a drug to control pain and inflammation in the diseases of the locomotor system, the physician should balance between the effectiveness and the most common side effects (gastrointestinal, cardiovascular).
|Number of pages||7|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Jul 1 2008|
ASJC Scopus subject areas